摘要
目的观察舒洛地特联合缬沙坦治疗DN(Ⅳ期)的疗效。方法 86例DN(Ⅳ期)患者常规治疗后随机分为两组,缬沙坦组口服缬沙坦胶囊,舒洛地特组在口服缬沙坦胶囊的同时肌注舒洛地特注射液,两周后口服舒洛地特胶囊。两组均治疗3个月。检测治疗前后SBP、DBP、Scr、BUN、UA、血清胱抑素C(Cys-C)、24h尿钠排泄量、24hUA1b、尿β2-微球蛋白(β2-MG)、尿α1微球蛋白(α1-MG)、尿N-乙酰-β-D葡萄糖苷酶(NAG)。结果与治疗前相比,两组Scr、BUN、UA无明显变化(P>0.05),SBP、DBP、Csy-C、24hUA1b、24h尿钠排泄量、尿α1-MG、β2-MG、NAG明显降低(P<0.05或P<0.01)。治疗后,舒洛地特组Csy-C、24hUA1b、尿α1-MG、β2-MG、NAG明显降低(P<0.01)。结论舒洛地特联合缬沙坦治疗能更有效地降低DN患者的UA1b。
Objective To observe the effect of the combination therapy of sulodexide and valsartan in DN at stage Ⅳ.Methods Eighty-six patients with DN were randomized into valsartan group and sulodexide group.The valsartan group was treated with oral valsartan capsule,and the sulodexide group received valsartan capsule as add on therapy to sulodexide for muscular injection,and 2 weeks later sulodexide capsule was used for oral takig,for 3 months.Then,the SBP,DBP,serum creatinine（Scr）,BUN,UA,serum cystatin C,24 h natriuresis,24 h uric protein,urine β2-microglobulin（β2-MG）,α1-microglobulin（α1-MG）,and β-N-acetyglocosamidase（NAG） were measured.Results After treatment in the two groups,the levels of Scr,BUN,and UA（P0.05） showed no significantly changes,the SBP,DBP,serum cystatin C,24 h uric protein,24 h natriuresis,urine α1-MG,β2-MG,and NAG were significantly decreased（P0.05 or P0.01）,while the decrease in serum cystatin C,24 h uric protein,urine α1-MG,β2-MG,and NAG of the sulodexide group was more obvious（P0.01）.Conclusion Sulodexide combined with valsartan can decrease more effectively the urinary protein,improving the renal function of T2DM patients with DN.
出处
《中国糖尿病杂志》
CAS
CSCD
北大核心
2013年第2期136-138,共3页
Chinese Journal of Diabetes
